Zilebesiran & Blood Pressure Control: Addressing Baseline Characteristics in the KARDIA-2 Trial
The landscape of hypertension treatment is constantly evolving, with a growing focus on innovative therapies targeting novel pathways. Zilebesiran, a first-in-class RNA interference (RNAi) therapy, has recently garnered notable attention for its potential to revolutionize blood pressure management. This article delves into a recent discussion surrounding the KARDIA-2 trial – a pivotal study evaluating zilebesiran – specifically addressing concerns raised regarding baseline differences in patient characteristics between the zilebesiran and placebo groups. As of November 7, 2025, understanding these nuances is crucial for clinicians and patients alike as we navigate the integration of this promising new treatment option.
Understanding the KARDIA-2 Trial & Initial Findings
The KARDIA-2 trial investigated the efficacy and safety of zilebesiran in patients with essential hypertension who were inadequately controlled on three or more antihypertensive medications. The results, published in The new England Journal of Medicine in 2024, demonstrated substantial reductions in systolic blood pressure (SBP) with zilebesiran compared to placebo. However, as is common with clinical trials, a subsequent letter to the editor from Drs. Chen and Zhu highlighted observed differences in baseline characteristics - specifically Body Mass Index (BMI) and prior use of antihypertensive therapy – between the two treatment arms. This is a standard part of the scientific process, ensuring clarity and rigorous evaluation of research findings.
Clarifying Baseline Differences: Statistical Significance & Clinical relevance
The authors of the original KARDIA-2 publication acknowledged the observed numerical differences in baseline BMI and prior antihypertensive medication use. However, they clarified that these differences were not statistically significant across the overall study population or within specific subgroups based on background antihypertensive therapy. While formal P-values weren’t included in Table 1 of the original publication (following JAMA style guidelines), further analysis confirmed the lack of statistical importance.
Importantly, the magnitude of these differences was small. Mean BMI was consistently around 32.5 kg/m² in both the zilebesiran and placebo groups, and the proportion of patients with prior antihypertensive medication use ranged from 83% to 89% in the zilebesiran arm and 85% to 95% in the placebo arm. This suggests that any potential impact of these baseline differences on the study outcomes was likely minimal.
Moreover, previous research – including Phase 1 studies and the KARDIA-1 trial – indicated that zilebesiran does not have a significant effect on body weight. This further supports the conclusion that the observed BMI differences were unlikely to confound the results.
| Characteristic | Zilebesiran Group (Mean/%) | Placebo Group (Mean/%) |
|---|---|---|
| Mean BMI (kg/m²) | ~32.5 | ~32.5 |
| Prior Antihypertensive Use (%) | 83-89% | 85-95% |
Statistical Analysis & Covariate Adjustment
The KARDIA-2 statistical analysis plan prespecified adjustment for baseline SBP and estimated glomerular filtration rate (eGFR) as covariates. While BMI and the number of prior antihypertensive medications were not included in this primary analysis, the authors maintain that the small differences observed were unlikely to materially affect the study’s conclusions.Modern statistical modeling techniques, such as propensity score matching, could be employed in post-hoc analyses to further explore the potential impact of these baseline imbalances, though the initial data suggests minimal influence.
Real-World Implications & the Future of Z
Related reading